⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MNOV News
Medicinova, Inc.
2026 New Year’s Greetings from the CEO
globenewswire.com
MNOV
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
globenewswire.com
MNOV
Amyotrophic Lateral Sclerosis Market Outlook: Expanding Therapeutic Pipeline and Novel Drug Launches Propel Growth Throughout Forecast Period (2025-2034) | DelveInsight
prnewswire.com
NRSN
IONQ
MNOV
CLNN
RVSN
BIIB
ABSI
CLNE
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
globenewswire.com
MNOV
Message from the CEO to MediciNova Shareholders
globenewswire.com
MNOV
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
globenewswire.com
MNOV
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
globenewswire.com
MNOV
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
globenewswire.com
MNOV
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
globenewswire.com
MNOV
MediciNova to Present at the LD Micro Main Event XIX Investor Conference
globenewswire.com
MNOV